Stuart Handelsman
Nephrology · Atlanta, GANPI 1063444883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,722 and has fallen 58.3% since, to $718 in 2021.
Across 184 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$608
- Vifor Pharma, Inc.$558
- Amgen$385
- OPKO Pharmaceuticals, LLC$319
- Akebia Therapeutics Inc$312
- Mallinckrodt Hospital Products Inc.$260
- plus $1K from 13 others
Across 227 payments — averaging $3119.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$448K
- Bayer$151K
- Gilead$47K
- Eli Lilly$40K
- AstraZeneca$14K
- GSK$9K
- plus $50 from 1 others
What the payments were for
- Food & beverage$3,52998%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 28 | $608 |
| Vifor Pharma, Inc. | 30 | $558 |
| Amgen(2 entities) | 21 | $385 |
| OPKO Pharmaceuticals, LLC | 26 | $319 |
| Akebia Therapeutics Inc | 14 | $312 |
| Mallinckrodt Hospital Products Inc. | 11 | $260 |
| Nuwellis, Inc. | 6 | $255 |
| Otsuka America Pharmaceutical, Inc. | 12 | $225 |
| GSK | 6 | $126 |
| Daiichi Sankyo Inc. | 6 | $115 |
| Fresenius USA Marketing, Inc. | 5 | $88 |
| Johnson & Johnson | 4 | $77 |
| Mallinckrodt Enterprises LLC | 3 | $75 |
| AMAG Pharmaceuticals, Inc. | 4 | $66 |
| Travere Therapeutics, Inc. | 4 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Bayer | 1 | $24 |
| Sanofi | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aquadex$130
How this compares
$3,595 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Sheldon ShoreAtlanta$474K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Tarik LalwaniAtlanta$69K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.